Allarity Therapeutics IncNASDAQ:ALLR
- LAST PRICE1.2600
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.2600/ 2
- Ask / Lots1.3000/ 20
- Open / Previous Close--- / 1.2600
- Day Range---
- 52 Week Range
- Volume962
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALLR |
|---|---|---|
| 09:32 ET | 7172 | 1.23 |
| 09:37 ET | 140 | 1.22 |
| 09:39 ET | 3845 | 1.25 |
| 09:44 ET | 1030 | 1.23 |
| 09:48 ET | 1352 | 1.2209 |
| 09:51 ET | 100 | 1.24 |
| 09:53 ET | 1075 | 1.225 |
| 10:02 ET | 3200 | 1.21 |
| 10:04 ET | 1879 | 1.21 |
| 10:13 ET | 5000 | 1.2101 |
| 10:15 ET | 200 | 1.215 |
| 10:18 ET | 200 | 1.215 |
| 10:27 ET | 500 | 1.215 |
| 10:36 ET | 1000 | 1.215 |
| 10:38 ET | 316 | 1.215 |
| 10:42 ET | 600 | 1.215 |
| 10:45 ET | 250 | 1.215 |
| 10:56 ET | 100 | 1.22 |
| 11:00 ET | 150 | 1.22 |
| 11:03 ET | 1100 | 1.215 |
| 11:05 ET | 1095 | 1.21 |
| 11:09 ET | 821 | 1.22 |
| 11:36 ET | 1500 | 1.22 |
| 11:39 ET | 700 | 1.23 |
| 11:45 ET | 252 | 1.24 |
| 11:48 ET | 1750 | 1.2095 |
| 11:50 ET | 1100 | 1.2 |
| 11:52 ET | 200 | 1.2194 |
| 12:06 ET | 200 | 1.2 |
| 12:17 ET | 200 | 1.2013 |
| 12:37 ET | 120 | 1.211 |
| 12:46 ET | 100 | 1.22 |
| 12:57 ET | 800 | 1.2 |
| 01:02 ET | 500 | 1.2182 |
| 01:04 ET | 651 | 1.2272 |
| 01:18 ET | 2705 | 1.21 |
| 01:20 ET | 600 | 1.23 |
| 01:49 ET | 198 | 1.225 |
| 01:54 ET | 283 | 1.225 |
| 02:03 ET | 200 | 1.22 |
| 02:05 ET | 460 | 1.22 |
| 02:07 ET | 4400 | 1.22 |
| 02:09 ET | 1200 | 1.2294 |
| 02:14 ET | 5699 | 1.225 |
| 02:18 ET | 4399 | 1.225886 |
| 02:20 ET | 6780 | 1.24 |
| 02:21 ET | 200 | 1.24 |
| 02:27 ET | 250 | 1.25 |
| 02:32 ET | 100 | 1.24 |
| 02:34 ET | 100 | 1.245 |
| 02:38 ET | 100 | 1.245 |
| 02:41 ET | 7670 | 1.26 |
| 02:43 ET | 9456 | 1.28 |
| 02:45 ET | 100 | 1.28 |
| 02:48 ET | 1500 | 1.28 |
| 02:50 ET | 1605 | 1.265 |
| 02:52 ET | 825 | 1.265 |
| 02:54 ET | 5962 | 1.255 |
| 02:56 ET | 1100 | 1.25 |
| 02:59 ET | 1188 | 1.24 |
| 03:01 ET | 1800 | 1.245 |
| 03:30 ET | 5300 | 1.22 |
| 03:32 ET | 5087 | 1.235 |
| 03:33 ET | 7556 | 1.2309 |
| 03:35 ET | 200 | 1.23 |
| 03:48 ET | 222 | 1.23 |
| 03:50 ET | 617 | 1.23 |
| 03:51 ET | 17398 | 1.25 |
| 03:53 ET | 200 | 1.25 |
| 03:57 ET | 908 | 1.255 |
| 04:00 ET | 3605 | 1.26 |
Nov 18, 2024
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements, from 8:00AM ET on Monday Nov 18, 2024 by Dow Jones
8:00AM ET on Monday Nov 18, 2024 by Dow Jones
Nov 14, 2024
*DJ Allarity Therapeutics 3Q Loss $12.2M >ALLR, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
8:00AM ET on Thursday Nov 14, 2024 by Dow JonesAllarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 12, 2024
ALLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow JonesDEADLINE ALERT for ALLR, and COIN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders, from 11:04AM ET on Tuesday Nov 12, 2024 by Dow Jones
11:04AM ET on Tuesday Nov 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Allarity Therapeutics Inc | 1.8M | 0.0x | --- |
Dermata Therapeutics Inc | 1.7M | -0.1x | --- |
Kiromic Biopharma Inc | 1.7M | -0.1x | --- |
Panbela Therapeutics Inc | 1.7M | 0.0x | --- |
Biostax Corp | 1.9M | -1.2x | --- |
Entero Therapeutics Inc | 2.0M | -0.1x | --- |
Company Information
Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. It has in-licensed the intellectual property rights to develop, use and market stenoparib. Its DRP companion diagnostic platform is a predictive biomarker technology that employs complex systems biology and bio-analytics with a clinical relevance filter to bridge the gap between in vitro cancer cell responsiveness to a given therapeutic candidate and in vivo likelihood of actual patient benefit from that therapeutic candidate. Its DRP companion diagnostic platform provides a gene expression signature, which reveals whether a specific tumor in a specific patient is likely to respond to one of its therapeutic candidates.
Contact Information
- Headquarters
- 24 School St., 2Nd FloorBOSTON, MA, United States 02108
- Phone
- 401-426-4664
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Gerald McLaughlin
- President, Chief Development Officer
- Jeremy Graff
- Chief Executive Officer
- Thomas Jensen
- Chief Financial Officer
- Alexander Epshinsky
- Chief Scientific Officer
- Steen Knudsen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-879.07 |
Book Value | $-280.43 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
